Oncology
Oncology
Search
All hands-on deck to fight the ‘zombie’ rabies virus
We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
Uniting to stop rabies: a global and local endeavor
By collaborating together, we can stop rabies. Read how we are breaking down barriers through the power of partnerships to fight this deadly disease
Real stories, real impact: fighting rabies
The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
Rabies? Not in Mexico!
Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
„Medical innovations and healthcare for everyone“
African Americans are often excluded from healthcare options and medical innovations. We want to learn how we can better serve them.
World Rabies Day
World Rabies Day
Iclepertin
Iclepertin: GlyT1 inhibitor
Discover our careers
Discover our careers
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim
Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
More Green
More Green
Lung Diseases
Lung Diseases
Leptospirosis dogs pet owner guide
The disease can affect multiple organs in dogs, causing kidney damage, liver failure, and even death. The most effective prevention method is vaccination.
CPHI Survey
CPHI Survey
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550)
Triple agonist peptide
Triple agonist peptide
Companion Animals
Companion Animals
Ethics and Compliance
Consistent with the Core of our Leitbild and Code of Conduct, we act with integrity and are committed to conducting business in a lawful and ethical manner.
CT-155
Digital therapeutic
Boehringer Ingelheim Human Pharma Clinical Pipeline dynamic
Boehringer Ingelheim Human Pharma Clinical Pipeline dynamic
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Zongertinib (BI 1810631)
Zongertinib (BI 1810631)
Patient Centricity
Patient Centricity
GPP
GPP